

Medical Device Safety: What does “the future” really mean?

Sarah Jennings: Patient Safety Clinical Lead for Medical Devices at NHS Improvement

NAMDET Conference 2018

Progressively wider definitions of safety....

“The simplest definition of patient safety is the prevention of errors and adverse effects to patients associated with health care.” WHO website

“...avoiding injuries to patients from the care that is intended to help them”
Institute of Medicine



Safety is a moving target



“Patient safetyis concerned with errors of commission (doing the wrong thing) and errors of omission (failure to do the right thing) and is inextricably linked with the other aspects of quality”

Clinical effectiveness = the right thing to do

Patient safety = doing the thing right

QI = continual efforts to ensure we always do the right thing the right way?

Paradigm Shift



Pictures courtesy of Imaginarium Productions



Can it go wrong?

“Despite the best selection, training, experience, competence and intentions, all users of poorly designed medical devices, equipment and technologies will at least operate inefficiently and, at worst, make errors that can contribute to harm or death”. U.S. Food and Drug Administration 2015

IF THERE'S MORE THAN ONE WAY TO USE A DEVICE, AND ONE OF THOSE WAYS CAN RESULT IN PATIENT HARM, THEN SOMEONE WILL DO IT THAT WAY

WHAT CAN'T GO WRONG WON'T GO WRONG

Using a broad definition of Human factors & ergonomics



Key changes - increased traceability of devices

Improvement



Eudamed will be expanded - collating information on multiple pre- and post-market aspects



Increased focus on identification and traceability through a mandatory unique device identifier (UDI) that will be placed on all device labels



For devices other than class III implantable devices, health institutions will need to store and keep the UDI of the devices with which they have been supplied




Patients with implantable devices will receive implant cards linking the device with their identity

We want to support the NHS to become a system devoted to continuous learning and improvement of patient safety.

Increasing our understanding of what goes wrong in healthcare

Enhancing the capability and capacity of the NHS to improve safety

By tackling the major underlying barriers to widespread safety improvement





Development of the Patient Safety Incident Management System

“a single port of call for recording, accessing, sharing and learning from patient safety incidents, in order to support improvement in the safety of NHS-funded services at all levels of the health system”.

Introducing DPSIMS

The DPSIMS project offers an opportunity to use modern technology to improve the health service for patients and carers, healthcare staff, NHS organisations and decision-makers, so that time and energy can be invested in the right things: **working to reduce harm**.

DPSIMS's overarching vision statement:

“a **single port of call** for recording, accessing, sharing and learning from patient safety incidents, in order to support improvement in the safety of NHS-funded services at all levels of the health system”.

Rationalise NRLS & STEIS

Data analytics, free text analysis, collaborative insight building

Direct and via LRMS

Review and update

Both with national team, and with peers

‘True incidents’, plus unexpected poor outcomes, and risks


More and better resources and feedback

Less Acute-centric: works in GP, dentistry care homes, community, LA care etc

But not excluding private providers

What will PSIMS offer?

Journey to Learning




5 main “zones” of functions to support NHS Improvement’s statutory patient safety duties:

- *To collect and analyse information about what goes wrong in the NHS*
- *To provide advice and guidance on reducing the risks to patients...*
- *To help providers better understand what goes wrong in care*
- *To support increased transparency around patient safety data*

(NHSI 2017-19 Business Plan)

High level plan



- What problem are we trying to solve?
- Who are our users?
- What are their core needs?

- Testing hypotheses
- Building (disposable) prototypes
- Developing our understanding of users and their needs

- Joining up improved prototypes into an end-to-end “minimum viable product” (MVP)
- Piloting with providers and real data - closed (“private”, Nov-Feb) then open (“public”, Mar)
- Improving as we go
- Planning ahead

- Roll out
- Shut down NRLS and STEIS
- Continue to improve service forever

A single system for all National Patient Safety Alerts



MHRA summit for UK partners January 2018

“Many national bodies in England, Scotland, Wales, Northern Ireland, or those with a UK-wide remit, issue communications to the healthcare service asking for action to be taken to protect patient safety. These may be called alerts, bulletins, messages, notices or go by other names, and may be issued via the Central Alerting System or alternative systems, including in the devolved nations”

Many different styles



Dear Pharmacist,

VALPROATE PREGNANCY PI

We are writing to remind you of communicated in April 2018. Pa aware of the risks of taking valp packs of educational materials f required was given to GPs, spe <https://www.gov.uk/drug-safety-gps-specialists-and-dispensers>

In addition to giving patients the important that they receive the s with valproate medicines. Manu use in pregnancy. However, we supplied in pharmacy boxes (*w serious risk of ham with valpro provided with this medicine, eve

If pharmacists or pharmacies re the leaflet from the bulk product

MHRA <https://www.gov.uk/quick>

eMC <https://www.medicines.org>

Sanofi <http://www.sanofi.co.uk/>

For hard copies of all the inform UK-Medicalinformation@sanofi.

Valproate must no longer be us prevention programme in place. need to avoid becoming pregna that this is the case for their pati

Yours faithfully,

Dr Ian Hudson
Chief Executive
Medicines and Healthcare prod

This letter has been signed by tl

Dr Keith Ridge
Department of Health and Social Care



Supply Disrup

SDA/2018/002 Iss

Epanutin (phenytoin)

Summary

Pfizer will be out of stock o early December 2018.

Pfizer are the sole licenser directly interchangeable; si referral.

For action by

Care Trusts, Mental Health Specialist Trusts, Ambulan Offices, Community Trust

Action start date: 22/10/20

Action

Different formulations of pt monitoring is required. All i who prescribe, dispense o

All Patients

- General Practitione suspension. Early c the stocks at home the next 7-8 weeks
- If the patient has st required. These pa

If a patient does not have : followed:



Estates and

Reference: Iss
EFA/2018/006 22 Oct

Vernacare Vortex mace contamination mains w

Summary

We have been informed th number 1309094, do not c Fittings) Regulations (Bye inlet float valve means tha the mains water supply thi supply by the tank content

Action by Estates teams

- Bring this alert to the att
- Identify the locations of Vernacare
- Contact Vernacare to ar service visit, breakdown Section (please note the alert via email by 02/11/
- Risk Assess if hospital e the instructions in Apper sites. Then inform Vern: team implement this fix
- Fix label to front of mac mark that the work has l

Action by
• Estates Managers

Deadlines for action
Actions underway: Immedi
Actions complete: 29 Marc

Device details

The identity of each Vortex front bottom left hand come manufacture and electrical :

Affected machines are as

2017-08-17 v20



Date: 05 October 2018

Dear Healthcare Professional,

Allergan Pharmaceutic

Ozurdex 700 micrograms applicator

(Dexamethasone)

Batch Number	
E76937	
E77093	
E77113	
E77331	
E77512	
E78167	
E78897	
E79233	
E79272	
E79467	
E79891	
E80684	
E80824	
E81080	
E81350	
E82127	
E82509	

- Allergan Pharmaceutics single loose silicone pa from the needle sleeve along with the implant.
- Additional testing has sl defective units but defe
- Batches on the market available. However defe once sufficient defect fr
- A Dear Healthcare Prof see attached.

EL (18)A/16

Classification: Official



Resources to support safe and timely management of hyperkalaemia (high level of potassium in the blood)

8 August 2018

Alert reference number: NHS/PSA/RE/2018/006

Resource Alert

Potassium is essential for the body's normal function, including maintenance of normal heart rhythm. The way the body responds to hyperkalaemia – a higher than normal level of potassium in the blood – is unpredictable; arrhythmias and cardiac arrest can occur without warning. Hyperkalaemia can affect patients in hospital and being cared for at home.

Hyperkalaemia is a potentially life-threatening emergency which can be corrected with treatment.

Over a recent three-year period, the National Reporting and Learning System (NRLS) received 35 reports of patients suffering cardiac arrest while hyperkalaemic. These suggest that some healthcare professionals may not appreciate that clinical assessment, treatment and ongoing monitoring of hyperkalaemia is time critical.

Typical extracts from incident reports read:

"the patient had a raised potassium which required treatment and [a member of staff] apparently stated that the day team could deal with it."

"[Treatment for hyperkalaemia] was prescribed and administered at approx 16:30; however, no further review of the patient was undertaken and no repeat treatment or bloods were done until the patient arrested at 09:26."

Review of local guidance to manage hyperkalaemia found some examples that were not evidence-based, and/or were not written in a way that was easy to follow during an emergency.

This alert signposts to resources on the **NHS Improvement website** that can help organisations ensure their clinical staff have easily accessible information to guide prompt investigation, treatment and monitoring options. The resources include an example of how hospitals could make this easier for their staff by pre-preparing sets of the equipment, guidance and medication they would need in an emergency.

The resource webpage also includes short videos organisations can use to help frontline staff recognise that hyperkalaemia is a medical emergency and encourage them to familiarise themselves with local guidance and equipment.

Sharing resources and examples of work

If there are any resources or examples of work developed in relation to this alert you think would be useful to others, please share them with us by emailing patientsafety.enquiries@nhs.net

Actions


Who: All organisations providing NHS funded-care for adults or children where blood test results may be received and reviewed, including GP services*

When: To begin as soon as possible and be completed by 8 May 2019

- 1 Identify a senior clinician in the organisation to lead the response to this alert
- 2 Review or produce local guidance (including key steps or easy reference guides) for the management of hyperkalaemia that aligns with the evidence-based sources highlighted in the linked resources
- 3 Ensure that local guidance can be easily accessed by all staff including bank and agency staff
- 4 Ensure relevant guidance and resources are embedded in clinical practice by revising local training and audit
- 5 Use local communication strategies (such as the videos, newsletters, local awareness campaigns, etc) to make all staff aware that hyperkalaemia is a potentially life-threatening emergency and that its timely identification, treatment and monitoring during and beyond initial treatment is essential

*While general practices will not need hyperkalaemia treatment protocols or equipment, they will need to ensure they implement all actions that will support the right response to any blood test results they receive indicating hyperkalaemia.

Types/numbers of some safety communications sent via CAS



Issues:

- Feeling overwhelmed by communications (many local/regional)
- Tradition/custom and practice (from some decades past)
- Assumption alerts intended to warn individuals to try harder not to make mistakes leading to 'circulate and sign' approach
- Delegation to multiple units to act rather than coordinated efforts
- Not always on executive/senior/clinical leadership radar
- Alerts signed off as action completed without actions completed

What people wanted:

- Create a clear distinction between **requirements for organisational action by a specific date (NHSI leading)** and **messages conveying information for individuals to read and remember (MHRA leading)**
- Consistency of presentation of key content including clear actions
- Highlight those that need board/leadership involvement
- **Issue fewer of them, to increase focus on those that matter (but also noting issues they felt should have been alerts not letters/**

National Patient Safety Alert Committee

- The Committee will establish criteria to help NHS safety bodies give appropriate ‘national alert’ status to risks of death, disability or other serious harm. In turn this will make it easier for trusts, GPs and other NHS providers to understand when they need to coordinate urgent action to protect patients.
- The new National Patient Safety Alert Committee will agree common standards for those that require an immediate or co-ordinated response by providers.
- In future, an alert that requires complex action and organisational leadership will stand out.

Minister of State for Care Caroline Dinenage said:

“All NHS staff want to keep their patients safe and we will do our utmost to support them. The establishment of a National Patient Safety Alert Committee is another important intervention to ensure the NHS is supported to recognise, understand and implement the key steps that will reduce the risk of future tragedies - continuing our drive to making the NHS the safest healthcare system in the world.”

The Committee will be chaired by National Director of Patient Safety Aidan Fowler with Chief Inspector of Hospitals Ted Baker as deputy chair.

The Care Quality Commission will also monitor compliance with specific National Patient Safety Alerts as appropriate during their inspections with plans to roll out the current pilot approach to Trusts in the Autumn.

We've all been working on it

National Patient Safety Alert Committee

- All Alert issuers represented at highest levels + CQC
- Draws from past experience of accreditation for clinical guidelines (e.g. NICE and Royal College guidance) - *multiple issuing bodies, but users can trust 'kite marked' clinical guidance*
- Common standards, thresholds and formats to be mutually agreed (we're getting there) confirmed and maintained - *including an inherent need to set thresholds at a level that reduces overall numbers*
- 'Credentialing' is authorisation for the issuing body/team to designate a specific publication as a **National Patient Safety Alert** when these common standards are met - *not an extra committee approval stage for individual alerts*
- We've got consensus on principles, aiming to establish by late

2018



Improvement



Sign up to SAFETY



MEDICAL DEVICE SAFETY



National Reporting and Learning System



Stage Three: Directive
Improving medical device incident reporting and learning
20 March 2014



The AHSN Network

NHS Innovation Accelerator

“The best
way to
predict the
future is to
create it.”

or design it, or at the very least,
influence it!